MERCK & CO INC - WELIREG COMBINED WITH LENVIMA LOWERS DISEASE PROGRESSION RISK BY 30%

Written by Emily J. Thompson, Senior Investment Analyst

Source: moomoo

Updated: 2 days ago

0mins

MRK-1.95%

Should l Buy MRK?

Source: moomoo

Merck & Co. Announcement: Merck & Co. has reported that its drug, Lenviima, significantly reduces the risk of disease progression.
Efficacy Rate: The treatment is shown to lower the risk of disease progression by 30%, indicating a promising advancement in patient care.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on MRK

Wall Street analysts forecast MRK stock price to fall

16 Analyst Rating

11 Buy

5 Hold

0 Sell

Moderate Buy

Current: 123.820

Low

95.00

Averages

119.53

High

139.00

Current: 123.820

Low

95.00

Averages

119.53

High

139.00

RBC Capital

Outperform

initiated

$142

2026-02-24

Reason

RBC Capital

Price Target

$142

AI Analysis

2026-02-24

initiated

Outperform

Reason

RBC Capital initiated coverage of Merck with an Outperform rating and $142 price target. The firm sees the stock's investor enthusiasm continuing with near-term launches and Phase 3 readouts driving estimate upgrades. The Keytruda loss of exclusivity in late 2028 will be "de-risking" and management's a track record provides confidence in an early-2030s return to growth versus consensus which has Merck's erosion well into the mid-2030s, the analyst tells investors in a research note.

Barclays

Overweight

initiated

$140

2026-02-19

Reason

Barclays

Price Target

$140

2026-02-19

initiated

Overweight

Reason

Barclays initiated coverage of Merck with an Overweight rating and $140 price target. The firm says the company's 2026 will bring "first-in-class" launches and pivotal data readouts. Merck shares offer potential for both earnings upside and multiple expansion, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MRK

Unlock Now

About MRK

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Merck & Co Inc: FDA Establishes PDUFA Deadline of June 19, 2026 for Welireg and Keytruda

2 days agomoomoo

Merck & Co. Announcement: Merck & Co. has set a new date of June 19, 2026, for the FDA's decision regarding the approval of its drug, Welireg.
Key Drug Focus: The drug Welireg is significant for its potential impact on treatment options, particularly in the context of key health conditions.

FDA Grants Priority Review for Combination of Welireg and Keytruda by Merck & Co Inc.

2 days agomoomoo

Merck & Co. Update: Merck & Co. has received priority review from the FDA for its combination treatment involving Welireg and Keytruda.
Regulatory Milestone: The FDA's acceptance of the priority review signifies a potential advancement in treatment options for patients.

Combination of KEYTRUDA® (PEMBROLIZUMAB) and WELIREG® (BELZUTIFAN) as Adjuvant Therapy Lowers Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Early-Stage Renal Cell Carcinoma Patients

2 days agomoomoo

Key Findings: The combination of Keytruda (pembrolizumab) and Welireg (belzutifan) has been shown to reduce the risk of disease recurrence or death by 28% compared to Keytruda alone in certain patients.
Target Patient Group: This treatment is particularly effective for patients with early-stage renal cell carcinoma (RCC).

MERCK & CO INC - FDA AGREES TO EVALUATE TWO ADDITIONAL NDAs FOR WELIREG IN COMBINATION WITH LENVIMA

2 days agomoomoo

FDA Review: The FDA has accepted a review of two supplemental applications from Merck & Co. for their product, Welireg.
Product Focus: The review pertains specifically to the use of Welireg in treating certain conditions, highlighting its potential benefits in the medical field.

MERCK & CO INC - WELIREG COMBINED WITH LENVIMA DEMONSTRATES NOTABLE ENHANCEMENT IN PROGRESSION-FREE SURVIVAL

2 days agomoomoo

Significant Improvement: Merck & Co's Lenviima shows notable progress in free survival rates for patients.
Clinical Advancements: The findings indicate a substantial enhancement in treatment outcomes for those undergoing therapy.